{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:17:37Z","timestamp":1791249457919,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1245\/s10434-016-5300-6","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T18:55:03Z","timestamp":1467917703000},"page":"4110-4114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon \u03b12b Formulated in Syn3 for Failures of Bacillus Calmette\u2013Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1245","volume":"23","author":[{"given":"Neema","family":"Navai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Benedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ainslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Barton","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P. N.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"5300_CR1","first-page":"1124","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. JURO. 2000;163:1124\u20139.","journal-title":"JURO"},{"key":"5300_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","volume":"62","author":"DR Yates","year":"2012","unstructured":"Yates DR, Brausi MA, Catto JWF, et al. Treatment options available for bacillus Calmette\u2013Gu\u00e9rin failure in non-muscle-invasive bladder cancer. Eur Urol. 2012;62:1088\u201396. doi: 10.1016\/j.eururo.2012.08.055 .","journal-title":"Eur Urol"},{"key":"5300_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639\u201353. doi: 10.1016\/j.eururo.2013.06.003 .","journal-title":"Eur Urol"},{"key":"5300_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.juro.2009.11.038","volume":"183","author":"RS Svatek","year":"2010","unstructured":"Svatek RS, Fisher MB, Matin SF, et al. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. JURO. 2010;183:929\u201334. doi: 10.1016\/j.juro.2009.11.038 .","journal-title":"JURO"},{"issue":"3","key":"5300_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus-mediated interferon-\u03b12b formulated in Syn3 for BCG failures in non-muscle-invasive bladder cancer. J Urol. 2013;190(3):850\u20136. doi: 10.1016\/j.juro.2013.03.030 .","journal-title":"J Urol"},{"key":"5300_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","volume":"10","author":"WF Benedict","year":"2004","unstructured":"Benedict WF, Tao Z, Kim C-S, et al. Intravesical Ad-IFN alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004;10:525\u201332. doi: 10.1016\/j.ymthe.2004.05.027 .","journal-title":"Mol Ther"},{"key":"5300_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","volume":"174","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden APM, Witjes JA, Kurth K. Bacillus Calmette\u2013Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. JURO. 2005;174:86\u201391. doi: 10.1097\/01.ju.0000162059.64886.1c .","journal-title":"JURO"},{"key":"5300_CR8","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette\u2013Gu\u00e9rin. URO. 2013;31:1635\u201342. doi: 10.1016\/j.urolonc.2012.04.010 .","journal-title":"URO."},{"key":"5300_CR9","doi-asserted-by":"crossref","unstructured":"Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette\u2013Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. JURO. 2000;163:761\u20137. http:\/\/eutils.ncbi.nlm.nih.gov\/entrez\/eutils\/elink.fcgi?dbfrom=pubmed&id=10687972&retmode=ref&cmd=prlinks .","DOI":"10.1016\/S0022-5347(05)67799-3"},{"key":"5300_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00345-011-0681-4","volume":"29","author":"DR Yates","year":"2011","unstructured":"Yates DR, Roupr\u00eat M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol. 2011;29:415\u201322. doi: 10.1007\/s00345-011-0681-4 .","journal-title":"World J Urol"},{"key":"5300_CR11","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G. Phase II trial of intravesical gemcitabine in bacille Calmette\u2013Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729\u201334. doi: 10.1200\/JCO.2005.05.2720 .","journal-title":"J Clin Oncol"},{"key":"5300_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","volume":"55","author":"A Shabsigh","year":"2009","unstructured":"Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164\u201376. doi: 10.1016\/j.eururo.2008.07.031 .","journal-title":"Eur Urol"},{"key":"5300_CR13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19:666\u201375.","journal-title":"J Clin Oncol"},{"key":"5300_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"R J\u00e4rvinen","year":"2009","unstructured":"J\u00e4rvinen R, Kaasinen E, Sankila A, Rintala E. Long-term efficacy of maintenance bacillus Calmette\u2013Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56:260\u20135. doi: 10.1016\/j.eururo.2009.04.009 .","journal-title":"Eur Urol"},{"key":"5300_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"O Nativ","year":"2009","unstructured":"Nativ O, Witjes JA, Hendricksen K, et al. Combined thermochemotherapy for recurrent bladder cancer after bacillus Calmette\u2013Guerin. JURO. 2009;182:1313\u20137. doi: 10.1016\/j.juro.2009.06.017 .","journal-title":"JURO"},{"key":"5300_CR16","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","volume":"24","author":"JM McKiernan","year":"2006","unstructured":"McKiernan JM. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24:3075\u201380. doi: 10.1200\/JCO.2005.03.1161 .","journal-title":"J Clin Oncol"},{"key":"5300_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","volume":"185","author":"PF Bassi","year":"2010","unstructured":"Bassi PF, Volpe A, D\u2019Agostino D, et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette\u2013Gu\u00e9rin refractory carcinoma in situ of the bladder: results of a phase I study. JURO. 2010;185:445\u20139. doi: 10.1016\/j.juro.2010.09.073 .","journal-title":"JURO"},{"key":"5300_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","volume":"186","author":"JM McKiernan","year":"2011","unstructured":"McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette\u2013Gu\u00e9rin refractory nonmuscle invasive bladder cancer. JURO. 2011;186:448\u201351. doi: 10.1016\/j.juro.2011.03.129 .","journal-title":"JURO"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5300-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T21:14:07Z","timestamp":1568150047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5300-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["5300"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5300-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}